Bladder Preservation Strategies

Jani, Ashesh B.; Efstathiou, Jason A.; Shipley, William U.

doi:10.1016/j.hoc.2014.10.004

Cited by 12 publications

(5 citation statements)

References 42 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bladder cancer has been known as one of the most frequent urological malignancies with a high incidence and mortality rate (1,2). Although recent advances in treatment have led to increased survival rates for patients with bladder cancer, the incidence and mortality rates are still increasing (3,4). Therefore, it is imperative to understand the basic mechanisms of bladder cancer progression and to find new biological targets and effective treatment strategies for bladder cancer prevention and treatment.…”

Section: Introductionmentioning

confidence: 99%

Induction of apoptosis by ethanol extract of <i>Citrus unshiu</i> Markovich peel in human bladder cancer T24 cells through ROS-mediated inactivation of the PI3K/Akt pathway

Ahn

Choi

Kwon

et al. 2017

BST

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Induction of apoptosis by ethanol extract of <i>Citrus unshiu</i> Markovich peel in human bladder cancer T24 cells through ROS-mediated inactivation of the PI3K/Akt pathway

Ahn

Choi

Kwon

et al. 2017

BST

View full text Add to dashboard Cite

“…Bladder preservation strategies aim to achieve a maximum control of cancer with the preservation of bladder function and subsequent benefits on quality of life and survival. In selected patients with MIBC, it has been shown that chemoradiation following an aggressive transurethral (TUR) resection of bladder tumor (TURBT) can be an effective and safe alternative treatment to radical cystectomy [ 30 ]. Although biomarker studies based on TURBT surgical specimens indicate that a favorable response to organ-preservation treatment using radiation therapy or chemotherapy regimens can be obtained in some subsets of patients, these observations should be validated in prospective studies.…”

Section: Bladder Preservation and New Molecular Classificationsmentioning

confidence: 99%

“…Long-term results were similar in both studies with complete response rates in 70% of patients, local control in 40–60%, distant metastasis in <40%, overall survival in 25–35%, salvage cystectomy in 20–30%, and bladder preservation in 80% of survivors. The pooled results of phase II and phase III studies showed complete response in 69% of patients, and 5- and 10-year rates of 56% and 55% for cystectomy-free survival, 71% and 65% for disease-specific survival, and 57% and 36% for overall survival, respectively [ 30 ].…”

Section: Bladder Preservation and New Molecular Classificationsmentioning

confidence: 99%

Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group

et al. 2021

View full text Add to dashboard Cite

This review presents challenges and recommendations on different aspects related to the management of patients with localized muscle-invasive bladder cancer (MIBC), which were discussed by a group of experts of a Spanish Oncology Genitourinary (SOGUG) Working Group within the framework of the Genitourinary Alliance project (12GU). It is necessary to clearly define which patients are candidates for radical cystectomy and which are candidates for undergoing bladder-sparing procedures. In older patients, it is necessary to include a geriatric assessment and evaluation of comorbidities. The pathological report should include a classification of the histopathological variant of MIBC, particularly the identification of subtypes with prognostic, molecular and therapeutic implications. Improvement of clinical staging, better definition of prognostic groups based on molecular subtypes, and identification of biomarkers potentially associated with maximum benefit from neoadjuvant chemotherapy are areas for further research. A current challenge in the management of MIBC is improving the selection of patients likely to be candidates for immunotherapy with checkpoint inhibitors in the neoadjuvant setting. Optimization of FDG-PET/CT reliability in staging of MIBC and the selection of patients is necessary, as well as the design of prospective studies aimed to compare the value of different imaging techniques in parallel.

show abstract

“…And the prognosis of MIBC patients are much worse compared with NMIBC patients, due to the high risk of cancer metastasis. For MIBC patients, the most utilized therapy contains radical cystectomy combined with chemoradiotherapy [4][5][6], and transurethral resection followed by intravesical chemotherapy is often selected as a standard-of-care (SoC) for NMIBC patients [7][8][9]. Platinum-based neoadjuvant chemotherapy has also been gradually considered as a SoC due to the improvement of patients' overall survival [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells

Zheng,

Shi,

Chen

et al. 2023

Aging

View full text Add to dashboard Cite

Background: Bladder cancer is one of the most common type of cancers globally, and the majority of cases belong to urothelial bladder carcinoma (UBC) type. Current researches have demonstrated that multiple genomic abnormalities are related to the sensitivity of cisplatin-based chemotherapy in bladder cancer patients. Previous findings have indicated a controversial role of Ubiquitin Carboxy-Terminal Hydrolase L1 (UCHL1) in malignancy, so we aimed to further explore the role of UCHL1 in UBC. Methods: UBC cell lines and The Cancer Genome Atlas (TCGA) in-silico datasets were utilized to investigate UCHL1 expression pattern and functional as well as prognostic impacts in UBC cancer cell line models and patients. UCHL1 overexpression and silencing vectors and subsequent immunoprecipitation/ubiquitination experiments in combination of cellular functional assays were conducted to explore UCHL1-PKM2 interaction axis and its significance in UBC malignancy. Results: UCHL1 was significantly up-regulated in UBC cancer cells and UCHL1 high-expression was associated with higher pathology/clinical grade and significantly inferior overall prognosis of UBC patients. UCHL1 interacted with PKM2 and enhanced PKM2 protein level through inhibition of PKM2 protein degradation via ubiquitination process. UCHL1-PKM2 interaction significantly promoted UBC cellular proliferation, metastasis and invasion activities. Conclusion: UCHL1-PKM2 interaction played an interesting role in UBC tumor cell proliferation, migration and metastasis. Our study suggests PKM2-targeted treatment might have a potential value in metastatic malignancy therapy development in the future.

show abstract

Bladder Preservation Strategies

Cited by 12 publications

References 42 publications

Induction of apoptosis by ethanol extract of <i>Citrus unshiu</i> Markovich peel in human bladder cancer T24 cells through ROS-mediated inactivation of the PI3K/Akt pathway

Induction of apoptosis by ethanol extract of <i>Citrus unshiu</i> Markovich peel in human bladder cancer T24 cells through ROS-mediated inactivation of the PI3K/Akt pathway

Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group

UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells

Contact Info

Product

Resources

About